Special Issue "Novel Drugs, Targets and Therapies against Infectious Diseases"

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Targeting and Design".

Deadline for manuscript submissions: 31 October 2023 | Viewed by 173

Special Issue Editors

Microbiology and Parasitology Lab, Research Institute of Biomedical Sciences IDIS, University Complex Hospital of Santiago de Compostela, Santiago de Compostela, Spain
Interests: system biology; immunoproteome; infectious diseases; sexual transmission diseases; mass spectrometry
Special Issues, Collections and Topics in MDPI journals
1. Director, Research and Development Rokote Laboratories Finland Oy, 00014 Helsinki, Finland
2. Adjunct Professor, Faculty of Pharmacy, University of Helsinki, 00014 Helsinki, Finland
Interests: cancer vaccines; vaccines for infectious diseases; cancer immunotherapy; oncolytic viruses; phage display; adenovirus; vaccinia; therapeutic antibodies

Special Issue Information

Dear Colleagues,

Currently, the treatment of infectious diseases has become substantially complicated and is therefore a serious problem in health and disease management. The increase in drug resistance, as well as the threat of new pandemics and emerging infections is a fact. This necessitates the development of new strategies, improved conventional antimicrobials drugs, or even completely new mechanisms of action.

The discovery of new compounds as candidates and the development of new strategies are essential scientifically, socially, and economically. On the other hand, improvements in bioinformatics and computational biology have increased the efficiency of many stages of the drug discovery pipeline or strategies. In fact, bioinformatics methods such as molecular dynamics, molecular docking or QSAR (including in silico methods) are strategically used when new drugs are considered for potential use, e.g., for SARS-CoV-2 infection.

This Special Issue on “Novel Drugs, Targets, and Therapies against Infectious Diseases” focuses on the identification and further optimization of corresponding compounds and strategies, for example, i) target-, ligand-, and computer-based approaches that involve biological evaluation, ii) drug design and drug formulation/delivery, and iii) molecular docking, molecular dynamics. Interdisciplinary studies are encouraged for submission.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

  • Phagotherapy;
  • Biological therapies, including peptides and antibodies;
  • Optimization of pipelines for personalized diagnosis;
  • Vaccines;
  • Bioinformatic approaches;
  • Drug formulation/delivery and targeted therapy;
  • New therapies and strategies to tackle resistance, infections, and oncolytic virus.

We look forward to receiving your contributions.

Dr. Eva Torres-Sangiao
Dr. Erkko O. Ylösmäki
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • infectious diseases
  • immunotherapy
  • vaccines
  • nanotechnology
  • drug formulation
  • targets
  • biological therapies

Published Papers

This special issue is now open for submission.
Back to TopTop